The proteins expressed by a genome have been termed the proteome.
Recently two strategies have dominated attempts to discover genes that underlie schizophrenia: linkagedisequilibrium studies and association studies. Both these approaches have disadvantages and have led to the publication of many conflicting reports. 5 Comparative brain proteome analysis is a new strategy that does not require an a priori theory of the pathogenesis of schizophrenia. It is a method that can potentially, and directly, identify proteins that are involved in the pathogenesis of schizophrenia.
Recent advances in protein chemistry, in particular the advent of two-dimensional gel electrophoresis (2DE), coupled with ultra-micro protein sequencing and computer-assisted gel comparison, now enable the characterisation of a significant proportion of a proteome ie those proteins expressed in a given tissue. 2 Five to seven amino acids of protein sequence, coupled with isoelectric point (PI) and molecular mass (M r ) data, can be derived from a single 2DE gel and are sufficient to characterise a protein if it is represented in a sequence databank. 6 Changes in concentration of specific proteins in a tissue are also detectable by 2DE and reflect either altered expression of a gene, changes in protein turnover or post-translational modifications. 7 Therefore, 2DE can be used to compare disease-affected tissue with unaffected tissue to detect proteins that are influenced by the disease process. This proteomic approach has previously been used to identify proteins of significance to the pathogenesis of multifactorial and oligogenic disorders such as heart failure 8 and lung carcinoma. 9 In the present study we set out to compare the hippocampal proteome between control, schizophrenic and AD individuals. AD is a brain disorder with a characterised molecular pathology whereas schizophrenia is a psychiatric disorder for which an organic basis has been proposed but not defined. 10, 11 The molecular events in AD, which lead to the formation of plaques, neurofibrillary tangles, apoptosis and subsequent loss of specific neurons, should lead to many changes in the hippocampal proteome. Therefore, we collected hippocampal tissue from seven schizophrenic, seven AD and seven control individuals, post mortem. The mean age and post mortem delay (PMD) of each patient group are detailed in Table 1 . Brain tissue was homogenised in a denaturing solution of urea and non-ionic detergent (see Materials and Methods) and the proteomes visualised by two-dimensional gel electrophoresis using immobilised pH 3-10 gradient isoelectric focusing in the first dimension and 12-14% gradient SDS-PAGE in the second dimension ( Figures  1 and 2 ). The resulting 2DE gels were silver stained, digitally scanned, features detected, quantified and matched using the Melanie II software package. Each feature corresponded to a protein of unique PI and M r . The optical density (OD) of features was proportional to protein concentration. Normalisation between gels was carried out by expressing features as a percentage of the sum of optical density for all features detected on the gel. Figure 1) . Circles denote the 73 proteins that were significantly increased in concentration and squares denote the 35 proteins that were significantly decreased in concentration (P Ͻ 0.05) in the AD hippocampus, when compared to the control hippocampus. Arrows indicate the proteins I and II, which were used to determine the relationship of age and PMD to protein concentration. The section of the gel between pH 8 and 10 contained no visible proteins and is not shown.
A mean of 1768 (s.d. 271) proteins were detected per gel (n = 21). A mean of 549 (s.d. 35) proteins, from each of the three groups, were matched successfully. The criterion for a successful protein match was that the Melanie software could detect and quantitate the protein in at least 12 of the 14 2DE hippocampal tissue gels in both the schizophrenia vs control and AD vs control analysis. The mean concentration of each matched protein in the diseased hippocampal proteome was statistically compared with the mean concentration of the same protein in the control hippocampus using the t-test (two-tailed, heteroscedastic). Nine proteins of significantly decreased and nine proteins of significantly increased concentration, were found in the schizophrenic hippocampus (P Ͻ 0.05) (Figure 1 ). In a similar comparison, 35 proteins were significantly decreased, and 73 proteins were significantly increased in concentration in the AD hippocampus (P Ͻ 0.05) ( Figure 2 ). In addition, 10 medial frontal gyrus tissue samples (schizophrenic n = 5 and control n = 5) were analysed by 2DE. This comparison yielded 587 proteins matched on the basis of being detected and quantified in nine out of 10 samples. Statistical analysis showed 14 significant (P Ͻ 0.05) concentration changes (data not shown).
One protein was chosen for characterisation because it was an abundant protein that was significantly decreased in concentration in both the schizophrenic (P = 0.03) and AD hippocampus (P = 0.0004). This protein was collected from preparative 2DE gels and subjected to trypsin digestion and the amino acid sequence of one of the resulting peptides was determined by Nterminal sequencing. This peptide sequence, TKPSDEEM, was used to probe multiple protein databases at the Mips Atlas web site (www. mips.biochem.mpg.de/mips/programs/atlas.html) and uniquely characterised the protein as DBI (acyl-CoAbinding protein, Swissprot accession No. P07108). The PI (6.11) and M r (9913) of DBI, obtained from the database entry, were consistent with the observed position of the protein on the 2DE gel ( Figure 1 ).
DBI is a monomeric protein that binds medium-and long-chain acyl-CoA esters with high affinity 12 and can down-regulate the action of GABA by binding to a benzodiazepine recognition site located on the GABA A receptor.
3 DBI is selectively expressed in glial cells located in circumventricular organs. 13 GABA A /benzodiazepine receptor binding has a potential role in the symptoms of schizophrenia.
14 Van Kammen et al 15 found that levels of CSF-DBI in chronic schizophrenic individuals increased following Haloperidol withdrawal. This effect was significantly greater in paranoid compared with chronic undifferentiated schizophrenic individuals. In a further study of drug-free chronic schizophrenics, Van kammen et al 16 found CSF-DBI concentrations were correlated with sleep REM latency. This correlation disappeared when patients were treated with Haloperidol. The changes in DBI concentration in the hippocampus, detected by our comparative proteome analysis, may also be a result of antipsychotic medication. Together these results sug-gest DBI may have a symptom modulatory role in schizophrenia.
Ferrarese et al 17 demonstrated increased CSF-DBI in AD, and demented patients with Parkinson's disease and Huntington's chorea. DBI can allosterically modulate GABAergic transmission so that when the dementia is severe the levels of hippocampal DBI may decrease in an attempt to elevate GABA levels. Alternately, selective glial cell loss may lead to both an increase in CSF-DBI and a decrease in hippocampal DBI.
The organic basis for schizophrenia is unknown, however, a number of abnormalities of the brain have been consistently described in individuals with schizophrenia. 18, 19 Cerebral ventricular enlargement stands as perhaps the most frequently confirmed neurobiological finding associated with schizophrenia. 20, 21 Enlargement of the CSF spaces implies that brain tissue volume is reduced in schizophrenia. This assumption has been confirmed by direct measurement using twin controlled magnetic resonance imaging and necropsy studies. 22 The brain regions most consistenty identified as contributing to this reduction in volume include the mesial cortices in the region of the hippocampal formation 23 and the prefrontal cortices. 24 Our proteome analysis revealed many significant changes in protein concentration in the AD hippocampus, involving 6% of the 2DE-observable proteome, that were not observed in the schizophrenic hippocampus ( Figure 2 ). Sixty-eight per cent of these changes were increases in concentration and may reflect aggregation of proteins into plaques within the AD hippocampus. Three of these changes in protein concentration, all reductions, were also found to occur in the schizophrenic hippocampus and included DBI. In studies of elderly hospitalised schizophrenics it has been suggested that schizophrenia can be a biological substrate for dementia. 25, 26 In contrast with AD, the changes in the schizophrenia hippocampal proteome involved less than 1% of the 2DE-observable proteome. Therefore, these findings suggest that the neuropathological presentation of schizophrenia is subtle. The schizophrenic, medial frontal gyrus, proteome also showed similar changes that involved less than 1% of the 2DE-observable proteome suggesting that this 'process' extends to the prefrontal cortex.
Possible confounding factors for the protein changes observed in AD are age and PMD (Table 1) . However, when the concentration of two other proteins (Proteins I and II, Figure 2 ), were examined in the control and schizophrenic groups, no correlation between protein concentration and age (r = −0.014, n = 28) or PMD (r = 0.076, n = 28) was evident ( Figure 3) . Therefore, neither age nor PMD, in themselves, are likely to cause the gross effects observed in the AD hippocampal proteome. These two proteins were chosen because they were both decreased in concentration in the AD hippocampus, and were of similar PI and %OD to DBI.
Many changes relating to the psychopathology or drug treatment of schizophrenia may have been overlooked in this study as the proportion of the proteome detectable by 2DE is less than 25%. In a group large enough to be statistically informative only one third of the detectable proteins can be matched. In addition, we estimate that only between four and six of the 18 protein changes, in the schizophrenic hippocampus can be characterised by trypsinisation and peptide sequencing. With the introduction of mass spectrometry to proteome analysis there will be a rapid increase in the power of this approach and a greater proportion of a proteome could be analysed. 27 In summary, our results indicate that the molecular events leading to schizophrenia and AD are reflected in the hippocampal proteome and that DBI is significantly reduced in both schizophrenia and AD. This may either be due to the disease process itself or due to the treatments for these disorders. Comparative proteome analysis therefore offers a novel method by which proteins important to the biological basis of psychopathology may be identified and characterised.
Materials and methods

Materials
Analytical grade chemicals were supplied by BDH Chemicals (Poole, UK). Phenylmethansulfonyl fluoride (PMSF) and iodoacetamide (IAA) were supplied by Sigma Pharmaceuticals (Sydney, Australia). Glutardialdehyde was supplied by Merck Sharp and Dohme (Sydney, Australia) and urea by Gibco BRL (New York, USA). Pharmalyte pH 3-10, Non linear (NL) Immobiline™ DryStrip (IPG) kits loading cups and ExcelGel™ precast 12-14% acrylamide SDS-gradient gels were all supplied by Amersham Pharmacia Biotech (Uppsala, Sweden). Melanie II 2D PAGE software was obtained from Biorad (Hercules, CA, USA). Sequencing grade modified trypsin was from Promega (Madison, WI, USA).
Tissue samples
Brain tissue was obtained from the NZ Neurological Foundation Human Brain Bank, at the Auckland School of Medicine, and the Mental Health Research Institute, Victoria, Australia. The brains were removed post mortem, dissected into anatomical areas and stored at −80°C. A pre-mortem diagnosis of schizophrenia was assigned according to DSM-III-R criteria by a registered psychiatrist. The post-mortem diagnosis of AD was made according to the CERAD neuropathology protocol, 28 based on histological examination of the brain and patient clinical history.
Tissue homogenisation
Samples of the hippocampus and medial frontal gyrus (150-400 mg) were homogenised in lysis solution (9 M urea, 2% v/v Triton X-100, 2% v/v pharmalyte pH 3-10, 0.13 M DTT, 8 mM PMSF, 3.5 l per mg of tissue), in a ground glass homogeniser pre-cooled on ice. The homogenate was then centrifuged at 7000 × g for 5 min and the supernatant stored at −80°C. 
Proteome analysis
The silver-stained 2DE gels were digitised at 125 × 125 pixels cm −1 using a Sharp JX-325 scanner and a green/blue filter. Gel features were detected, quantified, and matched, using the Melanie II software package, vol 2.1. For matching the image, size was reduced by a factor of two and the detection parameters were: smooths 2, Laplacian threshold 3, partials threshold 1, saturation 90, peakedness increase 100 and minimum perimeter 10. The matching of multiple features to one feature was not allowed.
Statistical analysis
The student's t-test was used to assess the statistical significance of the differences in the mean % ODs of proteins between the disease and control groups. The t-test statistic, two-tailed heteroscedastic equation was:
The parameter used to calculate the degrees of freedom was:
The null hypothesis, that there was no difference between the means, was tested to the 5% level of significance. Correlations were calculated using the equation:
x,y = cov(X,Y) x·y
Preparative 2DE gels Gels were stained with Coomassie Blue stain (2.3 mM Coomassie Brilliant Blue R250, 20% v/v methanol, 0.5% v/v acetic acid) for 2.5 h at 21°C with agitation.
The gels were destained in 30% v/v methanol for 16 h at 21°C with agitation.
In-gel protein digestion
In-gel digestion of Coomassie-stained proteins was based on the method of Hubbard. 29 The protein of interest was cut out of each gel and 9-12 spots were pooled, digested with modified trypsin, extracted and prepared for reversed phase HPLC.
Reversed-phase high performance liquid chromatography (RP HPLC)
The peptide mixture, from in-gel digests, was separated by RP HPLC at room temperature using an Applied Biosystems Brownlee C8 microbore column (220 × 2.1 mm, 7 m bead diameter) that was equilibrated for 10 min in a 10:1 solvent A (1% v/v TFA): solvent B (0.8 M acetonitrile in 0.085% v/v TFA) mixture. The sample was diluted from 40 l to 100 l in solvent A and loaded onto the column. A linear gradient of solvent B was used, increasing from 10% to 70% over 45 min and ramped to 80% for an additional 5 min, at a flow rate of 200 l min −1 . The optical density was monitored at 214 and 280 nm and peptide peaks collected.
N-terminal and internal sequence analysis
Sequence analysis was carried out on selected RP HPLC peaks using an Applied Biosystems Procise Sequencer, model 492.
